Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Enterprise Value (2016 - 2025)

Historic Enterprise Value for China Pharma Holdings (CPHI) over the last 17 years, with Q3 2025 value amounting to -$300000.0.

  • China Pharma Holdings' Enterprise Value rose 5825.74% to -$300000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$300000.0, marking a year-over-year increase of 5825.74%. This contributed to the annual value of -$626879.0 for FY2024, which is 5597.26% up from last year.
  • Latest data reveals that China Pharma Holdings reported Enterprise Value of -$300000.0 as of Q3 2025, which was up 5825.74% from -$625032.0 recorded in Q2 2025.
  • China Pharma Holdings' 5-year Enterprise Value high stood at -$300000.0 for Q3 2025, and its period low was -$4.9 million during Q4 2021.
  • Its 5-year average for Enterprise Value is -$1.4 million, with a median of -$901910.0 in 2023.
  • As far as peak fluctuations go, China Pharma Holdings' Enterprise Value tumbled by 59496.75% in 2022, and later skyrocketed by 6858.66% in 2023.
  • China Pharma Holdings' Enterprise Value (Quarter) stood at -$4.9 million in 2021, then skyrocketed by 58.22% to -$2.0 million in 2022, then increased by 29.86% to -$1.4 million in 2023, then soared by 55.97% to -$626879.0 in 2024, then surged by 52.14% to -$300000.0 in 2025.
  • Its Enterprise Value stands at -$300000.0 for Q3 2025, versus -$625032.0 for Q2 2025 and -$412688.0 for Q1 2025.